{'fraction_non_alphanumeric': 0.029411764705882353, 'fraction_numerical': 0.008021390374331552, 'mean_word_length': 6.133333333333334, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Strontium fructose 1,6‐diphosphate alleviates early diabetic testopathy by suppressing abnormal testicular matrix metalloproteinase system in streptozocin‐treated rats

Objectives Male hypogonadism is frequently associated with testopathy in patients with type 2 diabetes and in middle‐aged males. We hypothesized that abnormal matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) in testis have large roles to play in male hypogonadism. It has been found in diabetic rats that a novel compound, strontium fructose 1,6‐diphosphate (FDP‐Sr), with extra high energy supply, could reverse male hypogonadism by normalizing MMP‐9 and TIMPs in the testis. We investigated whether FDP‐Sr could be promising in treating diabetic testopathy.